Quiet Capital Leads $20M Seed for Tissue Testing Startup Polyphron
Fundraise Insider tracks newly funded startups each week and delivers verified sales leads of C-suite contacts straight to your inbox, so you reach the right people while the funding is still fresh. See pricing.
Polyphron has raised $20 million in Seed financing to build a platform that pairs artificial intelligence with automated human tissue manufacturing and biological simulation. Quiet Capital led the round, with Gradient, Haystack, and Compound participating.
The company is based in New York. It is going after a constraint that gets worse as AI drug discovery accelerates: generating potential drugs and biological hypotheses is now faster than the infrastructure available to validate them in human biology.
Every existing option forces a tradeoff between speed, cost, and biological relevance. Clinical trials give human data but cost a great deal and take years. Animal studies, simpler lab models, and computational simulations may miss the multicellular processes that shape how a person actually responds to a treatment.
Polyphron’s answer is what it calls Tissue Testing Environments, combining physical human micro-tissues with AI models trained on longitudinal data from those tissues. Two components do the work. The Tissue Foundry is an automated platform that grows human micro-tissues from stem cells using developmental signals meant to reproduce aspects of tissue formation. The Tissue World Model uses data from tissue trajectories to simulate responses to genetic, chemical, biological, and environmental changes across different donors. Together they form a loop where models make predictions, those predictions get tested against living human tissue, and the resulting data improves the next generation of models.
Cardiac tissue comes first and is already in production at the tissue foundry across multiple donor lines, with a broader donor panel being added to capture more of the variation found across human populations. Liver tissue follows in 2026, extending the same manufacturing, automation, and measurement stack into drug metabolism and liver toxicity.
Practical uses include checking whether a drug candidate might cause cardiac or liver toxicity before it enters clinical development, and working out which patient populations are more likely to respond to a given intervention. The longer-term goal is models that can predict how interventions behave across biologically diverse populations before trials begin.
The reasoning behind the bet is straightforward. If generative AI keeps cutting the cost and time of proposing new therapeutic candidates, physical testing capacity becomes the bottleneck. Michael Bloch of Quiet Capital put it in economic terms, arguing that making tissue a manufacturable, testable unit at scale changes the economics of drug development.
Co-founder and CEO Matthew Osman started the company with chief scientific officer Fabio Boniolo, who previously worked at Dana-Farber Cancer Institute, the Broad Institute, and Harvard Medical School. Vinh Q. Tran recently joined as a co-founder and chief AI scientist after working on post-training and self-improvement research for Gemini at Google DeepMind. Chief operating officer George Pilitsis founded and scaled the Datapoints product line at Ginkgo Bioworks.
The round gives the biotech company room to expand tissue manufacturing and AI infrastructure as it moves past cardiac models into additional tissue systems.
Suppliers and service firms selling into drug developers and research labs can receive verified contacts at newly funded life science companies every week through Life Science Lead Generation.